|

Human plasma derived antithrombin Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 3: 1

Top Sponsors

  • Octapharma1

Indications

  • Acquired Antithrombin Deficiency1
  • Heart Disease1

Stanford, California1 trial

Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass

Stanford University School of Medicine

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.